Skip Navigation



Annals of Oncology Advance Access published online on January 15, 2009
Annals of Oncology, doi:10.1093/annonc/mdn669
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/4/609    most recent
mdn669v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fasano, J.
Right arrow Articles by Muggia, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fasano, J.
Right arrow Articles by Muggia, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

review

Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development

J. Fasano1 and F. Muggia2,*

1 Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, Commack
2 Oncology Department, NYU Cancer Institute, New York, USA

* Correspondence to: Dr. F. Muggia, MD., NYU Cancer Institute, 550 First Avenue, NY 10016, USA. Tel: +1-212-263-6485; Fax: +1-212-263-8210; E-mail: franco.muggia{at}nyumc.org

To date, the presence of a hereditary background has not influenced the selection of drug treatment in breast cancer. However, increasingly, negative hormone receptors and Her2 (often referred to as ‘triple negative’) or a medullary carcinoma histology has been reported in BRCA mutation carriers. Accordingly, such patients are often considered for adjuvant protocols based on chemotherapy (and not based on endocrine manipulations or trastuzumab). Mouse models introducing a conditional BRCA-null expression in the breast have recently provided powerful support for cisplatin-based treatment and have implications for the design of adjuvant studies in these patients.

BRCA, triple negative, breast cancer, PARP1 inhibitor, cisplatin

Received for publication September 4, 2008. Accepted for publication September 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Frasci, G. D'Aiuto, P. Comella, M. D'Aiuto, M. Di Bonito, P. Ruffolo, G. Iodice, A. Petrillo, S. Lastoria, P. Oliviero, et al.
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908
Ann. Onc., October 8, 2009; (2009) mdp356v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Muggia
BRCA-deficient animal models and cisplatin resistance
Ann. Onc., May 1, 2009; 20(5): 962 - 962.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.